Tag Archives: targeted therapy

ASCO Stock and News Update: ARIA, BMY, EXEL, XBI

Biopharmaceutical stocks got a boost today from a rally in NASDAQ stocks and some positive news on cancer drugs from ASCO. The IBB ($106.36) was up 1.6% off its YTD and all time high of $110 and  a nice rally after five days of weakness.The XBI was also up 1.97%. Many biotech stocks hit their [...]

Comments Off Continue Reading →

Innovation Drives Market Gains in Biopharmaceuticals

This article was published in Genetic Engineering News in the section “Wall Street Biobeat” on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains Emerging Technologies in Biomedicine-Continuing Series Published in Genetic Engineering News April 1 [...]

Comments Off Continue Reading →

Ariad (ARIA) and MolecularMD Collaborate in Companion Dx for CML

Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have spotlighted the  Company and potential news at the ASCO Meeting which is [...]

Comments Off Continue Reading →

Healthcare Start-Ups: What’s Hot?

Hot biomedical concepts: Software, mobile communications, ophthalmology,antibiotics,epilepsy,surgery,cancer, and publishing. On Thursday March 9 The Wall Street Journal published an excellent review of the Top 50 start-ups and the money raised.The leaders were technology companies with a WEB focus. With valuations for Facebook, Group-On and Twitter soaring there is some debate as to whether we are [...]

Comments Off Continue Reading →

Rodman&Renshaw Part 2:Rosetta Genomics(ROSG)and Response Genetics(RGDX)

Within the “diagnostics and tools” track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in development of microRNA-based diagnostics (miRview) for various cancers as well as for the identification of the origin of [...]

Comments Off Continue Reading →

Response Genetics(RGDX) Signs Agreement with Glaxo for BRAF Gene

Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor samples. The BRAF gene encodes a protein involved in cell signaling and cellular growth and differentiation.Specific gene mutations have been correlated with the development of certain forms of cancer. [...]

Comments Off Continue Reading →